 Home > Biochemistry News > Biotechnology News > Targeted RNA-modifying enzyme $17 million upfront payment to help develop small molecule anti-cancer therapies

Targeted RNA-modifying enzyme $17 million upfront payment to help develop small molecule anti-cancer therapies

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

pde5 inhibitors list

cancer cell apoptosis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 14, 2021, Exelixis and STORM Therapeutics announced that they have reached a research and development cooperation agreement to jointly develop innovative small-molecule anti-cancer therapies that change the function of RNA

For RNA drugs, the main challenges it faces include: targeting the right tissue, pharmacokinetics, and stability

Tumor cells produce a large amount of adenosine deaminase called ADAR1, which reduces the ability of dsRNA to activate the immune system by editing double-stranded RNA (dsRNA) molecules

According to the terms of the agreement, Exelixis will pay STORM an upfront payment of US$17 million, obtain licenses for two discovery projects for RNA-modifying enzymes (including ADAR1), and provide funding for STORM's discovery research activities

Reference materials:

[1] Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express targeting RNA-modifying enzymes, US$17 million upfront payment to help develop small molecule anti-cancer therapies

10-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Targeted RNA-modifying enzyme $17 million upfront payment to help develop small molecule anti-cancer therapies

Related Articles

Express targeting RNA-modifying enzymes, US$17 million upfront payment to help develop small molecule anti-cancer therapies